不同剂量瑞舒伐他汀对冠心病合并高胆固醇血症患者血脂及血清高敏C反应蛋白的影响

Effect of Rosuvastatin with Different Doses on C-Reactive Protein and Blood-Fat in Patients Suffered from Coronary Artery Disease and Hypercholesteremia

关键词:  瑞舒伐他汀  冠心病  C反应蛋白  高胆固醇血症

Key words:  rosuvastatin  coronary artery disease  C-reactive protein  hypercholesteremia

摘要:

目的 对比不同剂量瑞舒伐他汀对冠心病(CAD)合并高胆固醇血症(HC)患者血脂及血清高敏C反应蛋白(HS-CRP)的影响，并评价其量效关系。方法 将60例CAD合并HC患者随机分为常规剂量组(10 mg·d^-1，C组)和大剂量组(40 mg·d^-1，H组)，各30例，分别测定服用相应剂量瑞舒伐他汀前及1个月后HS-CRP、血脂各成分及一般生化指标，并对2组结果加以比较。结果 治疗前2组间各指标均无差异，治疗1个月后2组LDL-C、TC、HS-CRP均较治疗前降低(P<0.05)，H组较C组降低更为明显(P<0.05)。LDL-C、TC下降与HS-CRP下降呈较显著正相关(P<0.01)。结论 瑞舒伐他汀可明显降低CAD合并HC患者血脂及HS-CRP水平，大剂量较常规剂量更为有效，降脂与降低CRP作用具有较好的相关性。

Abstract:

To investigate the level of high sensitivity C-reactive protein(HS-CRP) and blood-fat in patients suffered coronary artery disease with hypercholesteremia and the effect of rosuvastatin with different doses on it. METHODS Sixty patients with CAD and HC were assigned into common dose group(10 mg·d^-1, C group) and high dose group(40 mg·d^-1, H group), everyone was detected the level of HS-CRP and TC, TG, LDL, HDL before and 1 month after treated with rosuvastatin. RESULTS The level of CRP, LDL-C, TC was much reduced in both the two groups after therapy (P<0.05), while that of H group was even lower than C group (P<0.05). The change of CRP and LDL-C, TC showed a significant correlation (P<0.01). CONCLUSION Rosuvastatin can reduce the level of CRP and LDL, TC obviously. Besides, the effect showed a dose dependent.